艾维尔无心脏起器在中国患者中的安全性和有效性
Wuyang Zheng1, Ziguan Zhang1, Zuheng Liu1
1Department of Cardiology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China.
概括
在中国患者中,Aveir无心脏起器 (LP) 是安全有效的,其节奏参数得到改善,对心脏功能没有不良影响. 腹腔隔膜和自由壁植入部位都是可行的选择.
科学领域:
- 心脏病学 心脏病学
- 医疗器械 医疗器械
- 电力生理学 电力生理学
背景情况:
- 阿维尔无心脏起器 (LP) 是一种新型设备,正在获得临床采用.
- 它在中国人口中的使用尚未得到充分记录.
- 这项研究解决了对中国患者Aveir LP的有限数据.
研究的目的:
- 评估Aveir LP在中国患者中的安全性和有效性.
- 评估设备性能和对心脏功能的影响.
- 为了确定不同植入点的适用性.
主要方法:
- 对16名接受了Aveir LP植入的中国患者的回顾性分析.
- 植入右心室隔膜或自由壁中的植入.
- 在手术前和植入后一个月收集数据.
主要成果:
- 在所有16名患者中成功植入.
- 1个月后,节奏值,阻抗和R波传感显著改善.
- 没有观察到任何并发症或对心脏结构或功能的不良影响,包括三管吐.
结论:
- 在中国人群中,Aveir LP植入是安全有效的.
- 右心室隔膜和自由壁都是合适的植入点.
- 该设备表现出令人满意的性能,而不会影响右心脏功能.
相关概念视频
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...